This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Ceapro Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Ceapro.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Chemicals earnings growth	24.1%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 28

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ceapro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TSXV:CZO - Analysts future estimates and past financials data (CAD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	10	-5	-5	-4	N/A
9/30/2023	11	-3	-1	-1	N/A
6/30/2023	13	-1	0	0	N/A
3/31/2023	16	2	4	4	N/A
12/31/2022	19	4	6	7	N/A
9/30/2022	19	6	6	6	N/A
6/30/2022	20	6	4	5	N/A
3/31/2022	19	5	4	5	N/A
12/31/2021	17	3	3	4	N/A
9/30/2021	16	2	2	3	N/A
6/30/2021	15	1	3	4	N/A
3/31/2021	16	1	3	4	N/A
12/31/2020	15	2	4	4	N/A
9/30/2020	16	3	4	4	N/A
6/30/2020	16	2	2	3	N/A
3/31/2020	14	1	1	1	N/A
12/31/2019	13	-1	1	1	N/A
9/30/2019	14	-1	-1	0	N/A
6/30/2019	13	-1	-2	-2	N/A
3/31/2019	13	-1	-3	-2	N/A
12/31/2018	12	0	-3	-2	N/A
9/30/2018	10	-2	-2	0	N/A
6/30/2018	12	-2	0	2	N/A
3/31/2018	12	-1	-1	2	N/A
12/31/2017	13	-1	-2	2	N/A
9/30/2017	12	1	N/A	2	N/A
6/30/2017	12	1	N/A	2	N/A
3/31/2017	13	2	N/A	2	N/A
12/31/2016	14	4	N/A	5	N/A
9/30/2016	15	7	N/A	7	N/A
6/30/2016	15	7	N/A	7	N/A
3/31/2016	13	6	N/A	6	N/A
12/31/2015	11	5	N/A	4	N/A
9/30/2015	9	2	N/A	2	N/A
6/30/2015	9	1	N/A	1	N/A
3/31/2015	9	1	N/A	2	N/A
12/31/2014	9	2	N/A	2	N/A
9/30/2014	8	1	N/A	2	N/A
6/30/2014	8	1	N/A	1	N/A
3/31/2014	6	0	N/A	1	N/A
12/31/2013	7	0	N/A	0	N/A
9/30/2013	6	0	N/A	0	N/A
6/30/2013	6	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CZO's forecast earnings growth is above the savings rate (2.1%).

Earnings vs Market: Insufficient data to determine if CZO's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if CZO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CZO's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if CZO's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CZO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/06/03 16:37
End of Day Share Price	2024/06/03 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ceapro Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ahu Demir	NOBLE Capital Markets, Inc.
Cosme Ordoñez	NOBLE Capital Markets, Inc.
Nisha Hirani	Zacks Investment Research Inc.

This company is no longer active

Ceapro Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Ceapro Inc. Ordinary Shares to Be Deleted from OTC Equity

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.011 profit in 3Q 2022)

Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.021 profit in 2Q 2022)

The Returns At Ceapro (CVE:CZO) Aren't Growing

Ceapro Inc. Announces Resignation of Glenn Rourke as A Director

First quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.026 profit in 1Q 2022)

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

Full year 2022 earnings released: EPS: CA$0.056 (vs CA$0.037 in FY 2021)

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2A Human Clinical Trial Assessing Avenanthramide Tablets

Third quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.011 in 3Q 2021)

Ceapro Inc. Launches Next Phase of Scale Up for Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

Returns At Ceapro (CVE:CZO) Are On The Way Up

Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.009 in 2Q 2021)

Ceapro Inc. Appoints Sigrun Watson as Chief Revenue Officer

Ceapro's (CVE:CZO) Returns Have Hit A Wall

Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee

High number of new directors

First quarter 2022 earnings released: EPS: CA$0.026 (vs CA$0.007 in 1Q 2021)

Insufficient new directors

Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors

Full year 2021 earnings released: EPS: CA$0.037 (vs CA$0.024 in FY 2020)

Ceapro Inc., Annual General Meeting, Jun 01, 2022

Ceapro Appoints Ronnie Miller to its Board of Directors

Ceapro (CVE:CZO) Will Want To Turn Around Its Return Trends

Third quarter 2021 earnings released: EPS CA$0.011 (vs CA$0.002 in 3Q 2020)

Second quarter 2021 earnings released

Be Wary Of Ceapro (CVE:CZO) And Its Returns On Capital

Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as A Cholesterol-Lowering Agent

Ceapro's (CVE:CZO) Robust Earnings Are Supported By Other Strong Factors

First quarter 2021 earnings released

Estimating The Fair Value Of Ceapro Inc. (CVE:CZO)

Full year 2020 earnings released

New 90-day low: CA$0.63

Will Ceapro (CVE:CZO) Multiply In Value Going Forward?

Is It Too Late To Consider Buying Ceapro Inc. (CVE:CZO)?

New 90-day high: CA$0.79